According to a recent metanalysis, the frequency of ARID1A mutation and ARID1A protein expression loss in CRC patients was approximately 12–13% and was significantly associated with poorly differentiated grade and advanced tumor depth [34]. Here, ARID1A is linked to neoplasm.